Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck cancidas (caspofungin, legacy) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2022
6
Period ended Dec 31, 2022
Change on a year earlier
+50.0%
4 in FY2021
History
7 years
Since FY2016
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cancidas (caspofungin, legacy) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 6 | +50.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 4 | -42.9% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 7 | +16.7% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 6 | -50.0% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 12 | -40.0% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 20 | -20.0% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 25 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up cancidas (caspofungin, legacy) — u.s. sales ($m)
Cite this data
StockData. (2026). Merck Cancidas (caspofungin, legacy) — U.S. sales ($M) ($M), annual FY2016–FY2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_cancidas_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.